BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho CM, Chen HL, Hu RH, Lee PH. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Ther Adv Med Oncol 2019;11:1758835919843463. [PMID: 31065295 DOI: 10.1177/1758835919843463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel) 2022;14:1760. [PMID: 35406533 DOI: 10.3390/cancers14071760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
2 Biolato M, Galasso T, Marrone G, Miele L, Grieco A. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel) 2021;13:6337. [PMID: 34944957 DOI: 10.3390/cancers13246337] [Reference Citation Analysis]
3 Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19:2595-2601. [PMID: 32218809 DOI: 10.3892/ol.2020.11369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ho C. Editorial: Transplant Oncology of Liver Malignancies. Front Surg 2022;8:811223. [DOI: 10.3389/fsurg.2021.811223] [Reference Citation Analysis]
5 Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 16.5] [Reference Citation Analysis]
6 Lee A, Lee FC. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Front Med 2020;14:273-83. [PMID: 31863306 DOI: 10.1007/s11684-019-0728-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Zheng J, Luo J, Zeng H, Guo L, Shao G. 125I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma.Biomed Pharmacother. 2019;119:109402. [PMID: 31514072 DOI: 10.1016/j.biopha.2019.109402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Amjad W, Kotiah S, Gupta A, Morris M, Liu L, Thuluvath PJ. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. J Clin Exp Hepatol 2020;10:185-7. [PMID: 32189935 DOI: 10.1016/j.jceh.2019.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol 2022; 14(1): 163-180 [DOI: 10.4251/wjgo.v14.i1.163] [Reference Citation Analysis]
10 Ho CM, Hu RH, Wu YM, Ho MC, Lee PH. Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation. Clin Med Insights Oncol 2020;14:1179554920968774. [PMID: 33343205 DOI: 10.1177/1179554920968774] [Reference Citation Analysis]
11 Park R, Eshrat F, Al-Jumayli M, Saeed A, Saeed A. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E447. [PMID: 32784389 DOI: 10.3390/vaccines8030447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
12 Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019;1873:188314. [PMID: 31682895 DOI: 10.1016/j.bbcan.2019.188314] [Cited by in Crossref: 60] [Cited by in F6Publishing: 78] [Article Influence: 20.0] [Reference Citation Analysis]